QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient

Pierangelo Chinello; Nicola Petrosillo; Silvia Pittalis; Gianluigi Biava; Giuseppe Ippolito; Emanuele Nicastri; INMI Ebola Team

doi:10.1371/journal.pntd.0006034

QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient

PLoS Negl Trop Dis. 2017 Dec 28;11(12):e0006034. doi: 10.1371/journal.pntd.0006034. eCollection 2017 Dec.

Authors

Pierangelo Chinello¹, Nicola Petrosillo¹, Silvia Pittalis¹, Gianluigi Biava¹, Giuseppe Ippolito¹, Emanuele Nicastri¹; INMI Ebola Team

Affiliation

¹ Lazzaro Spallanzani National Institute for Infectious Diseases (INMI), IRCCS, Rome, Italy.

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Amides / adverse effects*
Amides / therapeutic use*
Antiviral Agents / adverse effects*
Antiviral Agents / therapeutic use*
Arrhythmias, Cardiac / chemically induced*
Ebolavirus / drug effects
Ebolavirus / pathogenicity
Electrocardiography
Hemorrhagic Fever, Ebola / drug therapy*
Hemorrhagic Fever, Ebola / virology
Humans
Italy
Levofloxacin / adverse effects
Levofloxacin / therapeutic use
Male
Pyrazines / adverse effects*
Pyrazines / therapeutic use*
RNA-Dependent RNA Polymerase / antagonists & inhibitors
Virus Replication / drug effects

Substances

Amides
Antiviral Agents
Pyrazines
Levofloxacin
RNA-Dependent RNA Polymerase
favipiravir

Grants and funding

The study was funded by Ricerca Corrente of the Italian Ministry of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.